The Clinically Sound Investor is a pharmacist for a large retail corporation, with a PharmD and a BA in psychology. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results.
His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
I have around eleven years of finance experience, of which six were gained in a ‘fast-stream’ career path as a bottom-up fundamental analyst with highly regarded investors. My most recent role was as an investment consultant with a former partner at one of London's most successful hedge-funds and we were looking to launch a new fund together. Before that, I was the senior analyst at a Goldman Sachs spin-out fund seeded by a top 50 hedge-fund of funds. I'm ready to step up to a position as a PM but am very open to positions as an analyst. I started my career in corporate finance and was a Goldman Sachs summer intern. I also have experience as a quant in the systematic equity investment space. I am passionate about investing and I come with excellent references from impressive individuals; I am now seeking my next challenge.